Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.35 |
| ▸ | CPN1 | P15169 | 4/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.35 |
| ▸ | USP19 | O94966 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15019398 | 1.00 | DPP4 (0.35) | DPP4DPP7CPN1CPB2USP19 | |
| SCHEMBL28919899 | 0.88 | CPN1 (0.42) | DPP4DPP7CPN1CPB2ALDH1A1 | |
| SCHEMBL22207510 | 0.88 | CPN1 (0.42) | DPP4DPP7CPN1CPB2ALDH1A1 | |
| SCHEMBL8513454 | 0.87 | CPN1 (0.37) | DPP4DPP7CPN1CPB2DPP8 | |
| SCHEMBL321299 | 0.82 | RIPK1 (0.35) | — | |
| SCHEMBL26694725 | 0.80 | DPP4 (0.36) | DPP4DPP7CPN1CPB2DPP8 | |
| SCHEMBL13035374 | 0.79 | CPN1 (0.38) | DPP4DPP7CPN1CPB2DPP8 | |
| SCHEMBL14167608 | 0.78 | CPN1 (0.37) | DPP4DPP7CPN1CPB2DPP8 | |
| SCHEMBL25291875 | 0.78 | CPN1 (0.37) | DPP4DPP7CPN1CPB2DPP8 | |
| SCHEMBL22233424 | 0.78 | CPN1 (0.37) | DPP4DPP7CPN1CPB2DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694330-B1 | INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11161854-B2 | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210188863-A1 | INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161854-B2 | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, GRK2, CLK2 | DPP4 3825/4885DPP7 2801/4885CPN1 2612/4885 |
| US-20210188863-A1 | INDAZOLYL-SPIRO[2.2]PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, GRK2, CLK2 | DPP4 3825/4885DPP7 2801/4885CPN1 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.